Form 4: Lantern Pharma Director Silberstein Acquires 10,000 Stock Options

David S. Silberstein, a director of Lantern Pharma Inc., acquired 10,000 stock options on July 15, 2024, under the company's Amended and Restated 2018 Stock Incentive Plan.

Summary

• On July 15, 2024, David S. Silberstein, a director of Lantern Pharma Inc., acquired 10,000 stock options.
• The options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan.
• The exercise price for both sets of options is $4.35.
• 5,000 options vest in equal monthly increments over 24 months, commencing August 15, 2024.
• The other 5,000 options vest in equal monthly increments over 36 months, commencing August 15, 2024.
• The options expire on July 15, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options by a director can be interpreted as a sign of confidence in the company, but it's a routine transaction.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, indicating a change in beneficial ownership by a company insider. Such filings are common and provide transparency into the trading activities of company directors and officers.

Stakeholder Impact

• The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.

Key Dates